Pharmaceutical Technology

DECEMBER 14, 2022

In September, Merck and Guardant Health expanded their partnership to expedite the development of precision oncology therapeutics. By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Gene Therapy 130

Gene Therapy Gene Development Manufacturing 130

pharmaphorum

FEBRUARY 15, 2021

A key objective is to create an oncology network or “hub” in the Campania region of Italy that will operate at a national and international level. The project will focus in part on developing tools and digital therapies (DTx) that are easily accessible, software-based and built on popular platforms, such as smartphones. .

Doctors 95

Doctors Doctor Medicine Development 95

Worldwide Clinical Trials

MARCH 12, 2024

Every step in a successful oncology study requires critical and carefully thought-out decisions. Biomarkers provide a rapid way to inform many clinical oncology study development decisions, including study endpoints. What are they, how do they work, and how can they benefit your oncology study?

Clinical Trials 159

Clinical Trials Clinical Trials Immune Response Trials 159

pharmaphorum

NOVEMBER 20, 2020

Gordon joins Prescient with more than 15 years of dedicated oncology experience in market research and competitive intelligence. Priya has co-authored several peer-reviewed scientific articles and industry-relevant white papers. Prior to joining Prescient, she served as a subject matter expert and trusted client advisor.

Marketing 64

Marketing Sales Production Licensing 64

Pharma Marketing Network

JULY 21, 2023

Some relevant groups to join include: Pharmaceutical Research and Manufacturers of America (PhRMA), Biotechnology Innovation Organization (BIO), and American Society of Clinical Oncology (ASCO). Be sure to post content that is relevant to the pharmaceutical industry and that is interesting and informative to your target audience.

Sales 52

Sales Development Clinical Trials Clinical Trials 52

Cloudbyz

JANUARY 27, 2021

For example, while virtual trials can eliminate the limitations due to geographical boundaries, it might be challenging to shift an oncology study in the virtual model. White Paper Download. White Paper Download. Understand global regulatory implications Federal laws and regulations heavily govern clinical trials.

Clinical Trials 98

Clinical Trials Clinical Trials Trials Packaging 98

The Pharma Data

MARCH 31, 2022

Black Americans experience disproportionate rates of cardiovascular disease,8 and – as a result of higher rates of asymptomatic PAD,9 less access to quality vascular care10 and greater risk for delays in care9 – are up to four times more likely than white Americans to have a PAD-related amputation.10. Source link: [link].

Cardiology 52

Cardiology Research Medicine Vaccination 52

The Pharma Data

DECEMBER 28, 2020

Scopus is a biopharmaceutical company whose lead drug candidate is a novel, targeted immuno-oncology gene therapy for the treatment of multiple cancers. Dr. Russell has managed all aspects of the drug development and regulatory approval processes for oncology and non-oncology drug candidates. David Weild IV.

Gene Therapy 52

Gene Therapy Life Science Gene Gene Editing 52

Worldwide Clinical Trials

DECEMBER 20, 2023

In November 2023, at Outsourcing Clinical Trials Dach in Zurich, our Executive Director, Oncology Strategy Lead, Matt Cooper , presented “Delivering Oncology Studies – Challenges and Considerations.” You can learn more about biomarkers and how to use them in oncology studies in this white paper.

Trials 188

Trials Clinical Trials Clinical Trials Drugs 188

Worldwide Clinical Trials

MARCH 1, 2024

Master protocols are frequently used in oncology trial designs and are expanding to other indications, including schizophrenia, Chron’s disease, Alzheimer’s disease, and pediatric Gaucher disease. Are there multiple viable indications to evaluate for your IP? Here are some relevant factors below: What Are the Advantages of a Master Protocol?

Trials 171

Trials Production Development Clinical Trials 171

pharmaphorum

SEPTEMBER 1, 2021

The new Cancer Care in Europe: Recovering from COVID-19 Disruption white paper assesses the disruption to patient care and the changes physicians implemented during the acute phase of the pandemic, with a focus on the way in which treatment strategies were altered.

110

110

pharmaphorum

JUNE 1, 2022

To improve outcomes for cancer patients and take advantage of the ground-breaking scientific and technological progress made in oncology prevention, diagnosis, therapy and care over recent years, it is of crucial importance to ensure all patients with cancer have an ongoing dialogue with the healthcare team. Finding out what patients want.

Sales 58

Sales Marketing 58

Worldwide Clinical Trials

NOVEMBER 21, 2023

He discovered an overactive pathway in his immune system and, with the help of his oncology team, began testing a drug approved for organ transplant rejection that could address the pathway. To learn more about the Every Cure and Worldwide partnership, listen to a recent podcast episode between Dr.

Clinical Trials 171

Clinical Trials Clinical Trials Clinical Development Drugs 171

The Pharma Data

MARCH 5, 2021

director of the CLL Program at Memorial Sloan Kettering Cancer Center and lead author of The Lancet paper. chief medical officer of Loxo Oncology at Lilly. chief medical officer of Loxo Oncology at Lilly. About Pirtobrutinib (LOXO-305). About the BRUIN Phase 1/2 Trial.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Development 52

pharmaphorum

SEPTEMBER 13, 2022

Noticing a pattern in the lymph nodes and spleen that indicated the appearance of disease, he published his findings in a paper entitled, ‘On Some Morbid Appearances of the Absorbent Glands and Spleen’. 1847 – Virchow links tumours and white blood cells. 1844 – First reported case of multiple myeloma.

Genome Project 98

Genome Project Genome Genomics DNA 98

pharmaphorum

OCTOBER 4, 2022

During the first stage of the initiative, more than 2,000 research papers were published, 49 clinical trials were carried out, and more than 30 patents were filed through the support of the US National Cancer Institute (NCI). These datasets are critical as a means to identify how molecular information affects clinical outcomes.”

Biobanking 105

Biobanking Clinical Trials Clinical Trials Trials 105

pharmaphorum

JUNE 29, 2022

There’s no reason to suppose that the innovative launches coming in from 2020 have suddenly become less innovative and significant in terms of commercial potential; most launches are entering the same types of therapy area – oncology, immunology and rare diseases – as before the pandemic, and the unmet need in these areas remains high.

Doctors 58

Doctors Doctor Sales Medicine 58

pharmaphorum

JANUARY 14, 2021

As interactive time with HCPs is likely to be scarce, companies need to be even more ruthless in prioritising content and in deciding what content to generate in the first instance – for example, in Real World Evidence, as outlined in IQVIA’s white paper, ‘Excellent Launches are winning the Evidence battle’ CNS (re) emerges.

Sales 68

Sales Marketing Production Medicine 68

Eye on FDA

NOVEMBER 18, 2021

Two recent white papers – one by Friends of Cancer Research and one by the Institute for Clinical and Economic Review (ICER) have outlined suggestions for reform to the accelerated approval program designed to make it more transparent and consistent.

Research 57

Research Clinical Research Medicine 57

Pharmaceutical Technology

MARCH 17, 2023

Between 2012 and 2022, the number of oncology risk sharing agreements increased massively by 498%. Watt said risk sharing agreements in oncology made up almost 50% of all pharmaceutical risk sharing agreements, as per a GlobalData analysis. This may be because access to oncology drugs varies widely across the world, she added.

Marketing 257

Marketing Drugs Research Analyst Manufacturing 257

Pharmaceutical Technology

FEBRUARY 20, 2023

Meanwhile, in clinical trials with available race data, white participants account for 59% of trial subjects, more than the combined total for all other racial categories. participation of white subjects. In addition, safety oncology and immunotherapy, which is a focus area for Cerba Research has close ties to virology.

Research 130

Research Clinical Trials Clinical Trials Trials 130

Pharmaceutical Technology

APRIL 6, 2023

Notably, oncology is the leading therapeutic area, with the highest percentage of new clinical development year-on year compared to other CGT therapy areas, indicating a high level of unmet needs and increased industry investment in the space.

Gene Therapy 130

Gene Therapy Gene Clinical Trials Clinical Trials 130

Pharmaceutical Technology

MARCH 8, 2023

Molecular science and technology firm Caris Life Sciences and Incyte have entered a strategic research collaboration to advance the latter’s oncology pipeline. The post Caris signs research partnership with Incyte for oncology pipeline appeared first on Pharmaceutical Technology. Please check your email to download the Whitepaper.

Research 130

Research Clinical Trials Clinical Trials Life Science 130

Pharmaceutical Technology

MARCH 9, 2023

Global biopharmaceutical firm UCB and Cancer Research UK have entered a multi-project partnership to advance two of the former’s oncology antibody candidates through clinical trials. It will combine Cancer Research UK’s oncology-focused translational research and clinical development capabilities and the antibody discovery expertise of UCB.

Antibody 130

Antibody Research Clinical Trials Clinical Trials 130

Pharmaceutical Technology

MARCH 20, 2023

Oncology and cardiovascular therapies were relatively low with 132 and 118 trials respectively. To learn more about how Oximio is unlocking the clinical trial potential of Africa, download the specially commissioned white paper below. Nigeria was the next highest with 169, followed by 163 in Kenya, and 160 in Uganda.

Clinical Trials 130

Clinical Trials Clinical Trials Trials Clinical Supply Chain 130

Pharmaceutical Technology

FEBRUARY 20, 2023

This white paper explores the roles immunohistochemistry (IHC), next-generation sequencing (NGS), and circulating tumour DNA (ctDNA) play in non-small cell lung cancer (NSCLC) precision medicine therapy development, and how they help healthcare providers determine the most effective treatment regimens for their patients.

Research 130

Research Clinical Trials Clinical Trials Clinical Research 130

Pharmaceutical Technology

MARCH 20, 2023

We believe that this antibody is a valuable addition to our immuno-oncology portfolio, whether used alone or in combination with our personalised immunotherapies.” “The data presented by OncoC4 on their ONC-392 antibody indicate a differentiated safety profile and encouraging clinical activity in various types of tumours. “We

Antibody 246

Antibody Development Trials Production 246

Pharmaceutical Technology

MARCH 20, 2023

Aside from a very slight rise in funding for genetic disorder treatments, investors’ order of priorities remains unchanged – with oncology still far and away the most actively funded area of research. But the headline figures are concealing some rising trends. One significant growth area is the rise of genomics.

Gene Therapy 225

Gene Therapy Genome Genomics Gene 225

Pharmaceutical Technology

JANUARY 12, 2023

For more information about how Baxter BioPharma Solutions manufacturing expertise can support your project, dow nload the paper below. . Download this whitepaper to find out more about oncology trends and how Baxter’s oncology contract manufacturing facility in Halle, Germany, minimise the risk of cross contamination.

Production 130

Production Contamination Development Manufacturing 130

Pharmaceutical Technology

FEBRUARY 24, 2023

AstraZeneca Oncology R&D Biologics Engineering & Oncology Targeted Delivery senior vice-president Puja Sapra said: “We are excited by the opportunity to accelerate the development of CMG901, a potential new medicine for patients with Claudin18.2-expressing expressing cancers.

Antibody 130

Antibody Development Engineer Clinical Trials 130

Pharmaceutical Technology

JANUARY 10, 2023

Last year, AstraZeneca acquired Neogene Therapeutics and announced a partnership with Huma Therapeutics within the oncology space. By downloading this Report, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Clinical Trials 246

Clinical Trials Clinical Trials Regulation Production 246

Pharmaceutical Technology

FEBRUARY 28, 2023

This licensing agreement will expand Chipscreen NewWay’s pipeline in the field of antibody drugs and immuno-oncology.” Chipscreen Biosciences CEO and president Dr Xianping Lu said: “Biocytogen’s YH008 has unique mechanisms and outstanding preclinical results.

In-Vivo 130

In-Vivo Antibody In-Vitro Licensing 130

Pharmaceutical Technology

DECEMBER 13, 2022

Koh is Chief Product Officer at Suvoda, a global clinical trial technology company that specialises in complex studies in therapeutic areas such as oncology, central nervous system (CNS), and rare disease.

Clinical Trials 261

Clinical Trials Clinical Trials Trials Production 261

Pharmaceutical Technology

FEBRUARY 17, 2023

The non-binding draft guidance gives insight into the agency’s current outlook and recommendations for standard and expedited programs in oncology. The agency proposes that pharma move away from the common maximum tolerated dose (MTD) to trial designs that prioritise drug dosage optimisation at different stages.

Clinical Trials 289

Clinical Trials Clinical Trials Trials Drugs 289

Pharmaceutical Technology

FEBRUARY 28, 2023

Celnova Pharma is an Argentina-based pharmaceutical company that centres its work around rare diseases, oncology, central nervous system, diabetes and critical care. HRA RD’s new partnership will function to allow HRA RD to launch its rare disease products Ketoconazole HRA and Lysodren across Argentina, Chile and Peru.

Marketing 130

Marketing Drugs Production Sales 130

Pharmaceutical Technology

DECEMBER 6, 2022

Within that figure, GlobalData estimates that around 60% of pipeline HPAPIs are developed to target oncology. HPAPIs may now represent more than 30% of the drug development pipeline.

Containment 130

Containment Development Drugs Contract Manufacturing 130

Pharmaceutical Technology

JANUARY 25, 2023

Others, like Elevation Oncology and Fate Therapeutics , have announced similar plans. While it is only January, several companies have already announced cuts and layoffs this year. UK-based biotech ReNeuron announced plans to lay off 40% of its employees , and Cyteir Therapeutics will be firing 70% of its staff.

Marketing 173

Marketing Life Science Pharma Companies Licensing 173